mibefradil has been researched along with Cancer of Prostate in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aceto, R; Bootman, MD; Chandler, S; Crea, F; Matheou, C; Mather, R; Pucci, P; Rietdorf, K; Rigas, SH; Silvestri, R; Venalainen, E; Wang, Y | 1 |
1 other study(ies) available for mibefradil and Cancer of Prostate
| Article | Year |
|---|---|
T-type calcium channels drive the proliferation of androgen-receptor negative prostate cancer cells.
Topics: Calcium Channel Blockers; Calcium Channels, T-Type; Cell Line, Tumor; Cell Proliferation; Ethosuximide; Humans; Male; Mibefradil; Molecular Targeted Therapy; PC-3 Cells; Prognosis; Prostatic Neoplasms; Receptors, Androgen; Up-Regulation | 2019 |